How much is Sonoma Biotherapeutics worth in 2026?

Sonoma Biotherapeutics has a current valuation of N/A based on their Early Stage VC (Series B) round and secondary market data.

How much funding has Sonoma Biotherapeutics raised?

Sonoma Biotherapeutics has raised N/A in total funding across 1 funding rounds.

Sonoma Biotherapeutics

Drug Discovery

Sonoma Biotherapeutics valuation and funding history | Last updated: August 4, 2021 | 1 funding rounds

Current Valuation

N/A

As of August 4, 2021

Total Funding Raised

N/A

Across 1 round

Last Round

Early Stage VC (Series B)

$265.0M

Last Funding

Aug 2021

Funding date

Capital Efficiency

N/A

Valuation / Funding

Funding History & Valuation Timeline

Complete history of all funding rounds and valuation milestones

Date	Round	Amount	Post-Valuation	Growth
August 4, 2021	Early Stage VC (Series B)	$265.0M	N/A	-

Valuation Analysis

Current Valuation Metrics

Sonoma Biotherapeutics is currently valued at N/A as of August 4, 2021.

Track Sonoma Biotherapeutics Valuation Updates

Get notified when Sonoma Biotherapeutics raises new funding or valuation changes

Explore More Data

Detailed analysis for Sonoma Biotherapeutics

Secondary Market Price

Real-time pricing data and trends

Valuation Tracker

Historical valuation changes

Funding History

Complete funding round timeline

Secondary Price History

Historical transaction data

All Investors

Complete list of all investors

View 5 companies free

Create a free account to unlock Sonoma Biotherapeutics's valuation history, funding rounds, and growth metrics.

No credit card required

What is Sonoma Biotherapeutics Worth in 2026?

Sonoma Biotherapeutics is a leading private company in the Drug Discovery sector. Track Sonoma Biotherapeutics's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.

How Sonoma Biotherapeutics Valuation is Determined

Private company valuations like Sonoma Biotherapeutics's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.